Literature DB >> 7589193

Antidepressant-like effect by postsynaptic 5-HT1A receptor activation in mice.

T Matsuda1, P Somboonthum, M Suzuki, S Asano, A Baba.   

Abstract

The antidepressant-like effect of 5-(3(-)[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy)-1,3- benzodioxole (MKC-242), a novel 5-HT1A receptor agonist, was studied in the forced swimming test in mice injected i.c.v. with 5,7-dihydroxytryptamine to destroy 5-HT neurons or treated with p-chlorophenylalanine to inhibit 5-HT synthesis. MKC-242 reduced immobility time of mice pretreated with vehicle and these drugs, although it did not affect their locomotor activity. The anti-immobility effect was antagonized by 5-HT1A receptor antagonists such as propranolol and N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropana mide. These findings support the hypothesis that postsynaptic 5-HT1A receptors play an important role in the antidepressant-like effect of 5-HT1A receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589193     DOI: 10.1016/0014-2999(95)00254-i

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects.

Authors:  Jeffery N Talbot; Emily M Jutkiewicz; Steven M Graves; Crystal F Clemans; Melanie R Nicol; Richard M Mortensen; Xinyan Huang; Richard R Neubig; John R Traynor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

Review 2.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 3.  The role of serotonin receptor subtypes in treating depression: a review of animal studies.

Authors:  Gregory V Carr; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2010-11-24       Impact factor: 4.530

Review 4.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

6.  Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.

Authors:  Minako Tajiri; Atsuko Hayata-Takano; Kaoru Seiriki; Katsuya Ogata; Keisuke Hazama; Norihito Shintani; Akemichi Baba; Hitoshi Hashimoto
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

7.  Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system.

Authors:  Franck Chenu; Denis J P David; Isabelle Leroux-Nicollet; Erwan Le Maître; Alain M Gardier; Michel Bourin
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

8.  Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT(1A) receptor-adenylyl cyclase axis.

Authors:  Adele Stewart; Biswanath Maity; Amanda M Wunsch; Fantao Meng; Qi Wu; John A Wemmie; Rory A Fisher
Journal:  FASEB J       Date:  2014-01-13       Impact factor: 5.191

9.  The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice.

Authors:  Masaki Sakaue; Yukio Ago; Akemichi Baba; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

10.  Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.

Authors:  A Newman-Tancredi; J-C Martel; M-B Assié; J Buritova; E Lauressergues; C Cosi; P Heusler; L Bruins Slot; F C Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2009-01-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.